Nektar Therapeutics (NKTR) FCF Margin (2010 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly FCF Margin of 408.03% in Q1 2026, down 36.94% quarter-over-quarter from 297.96% in Q4 2025, and up 6095.0% on a YoY basis from 6.59% in Q1 2025.
Nektar Therapeutics (NKTR) FCF Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 408.03% for Q1 2026.
- In Q1 2026, FCF Margin rose 6095.0% year-over-year to 408.03%; the TTM figure through Mar 2026 stood at 366.59% (down 16236.0% YoY), while the FY2025 annual figure was 377.83%, down 19782.0% from the prior year.
- FCF Margin was 408.03% for Q1 2026 at Nektar Therapeutics, down from 297.96% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 159.88% in Q4 2024 to a low of 468.98% in Q1 2025.
- Historically, FCF Margin has averaged 290.26% across 5 years, with a median of 264.34% in 2022.
- The sharpest annual moves came in 2022 and 2025: FCF Margin jumped 36517 bps in 2022, then sank 24832 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 264.34% in 2022, then climbed by 25 bps to 197.97% in 2023, then increased by 19 bps to 159.88% in 2024, then slumped by 86 bps to 297.96% in 2025, then sank by 37 bps to 408.03% in 2026.
- The last three FCF Margin figures came in at 408.03% (Q1 2026), 297.96% (Q4 2025), and 414.55% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | -408.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -408.03% |
| Dec 31, 2025 | -297.96% |
| Sep 30, 2025 | -414.55% |
| Jun 30, 2025 | -409.62% |
| Mar 31, 2025 | -468.98% |
| Dec 31, 2024 | -159.88% |
| Sep 30, 2024 | -184.87% |
| Jun 30, 2024 | -161.30% |
| Mar 31, 2024 | -222.03% |
| Dec 31, 2023 | -197.97% |
| Sep 30, 2023 | -174.59% |
| Jun 30, 2023 | -252.13% |
| Mar 31, 2023 | -242.42% |
| Dec 31, 2022 | -264.34% |
| Sep 30, 2022 | -351.61% |
| Jun 30, 2022 | -351.04% |
| Mar 31, 2022 | -373.16% |
| Dec 31, 2021 | -629.51% |
| Sep 30, 2021 | -417.61% |
| Jun 30, 2021 | -304.21% |